Axsome Therapeutics, Inc. $AXSM Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lessened its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 11.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,027 shares of the company’s stock after selling 3,613 shares during the period. Y Intercept Hong Kong Ltd owned 0.05% of Axsome Therapeutics worth $3,282,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of AXSM. Versant Capital Management Inc raised its stake in Axsome Therapeutics by 20,300.0% during the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock valued at $25,000 after acquiring an additional 203 shares during the last quarter. First Horizon Corp acquired a new stake in shares of Axsome Therapeutics during the third quarter worth $34,000. Covestor Ltd grew its position in Axsome Therapeutics by 294.5% in the 3rd quarter. Covestor Ltd now owns 501 shares of the company’s stock valued at $61,000 after buying an additional 374 shares during the last quarter. Wilmington Savings Fund Society FSB increased its stake in Axsome Therapeutics by 4,375.0% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 716 shares of the company’s stock valued at $87,000 after buying an additional 700 shares during the period. Finally, Ameritas Advisory Services LLC acquired a new stake in shares of Axsome Therapeutics in the 2nd quarter worth $77,000. 81.49% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AXSM. B. Riley began coverage on Axsome Therapeutics in a report on Wednesday, October 1st. They issued a “buy” rating and a $179.00 price objective on the stock. TD Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a research report on Wednesday, December 31st. Royal Bank Of Canada boosted their target price on shares of Axsome Therapeutics from $212.00 to $219.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Needham & Company LLC reiterated a “buy” rating and issued a $225.00 price target on shares of Axsome Therapeutics in a report on Monday, January 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Wednesday, January 21st. Nineteen investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $203.17.

Insider Buying and Selling

In other news, insider Ari Maizel sold 7,500 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $184.44, for a total transaction of $1,383,300.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Mark E. Saad sold 37,577 shares of Axsome Therapeutics stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total transaction of $6,206,968.86. Following the sale, the director directly owned 10,002 shares in the company, valued at $1,652,130.36. This trade represents a 78.98% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 440,403 shares of company stock valued at $67,191,178. Corporate insiders own 22.40% of the company’s stock.

Axsome Therapeutics Price Performance

AXSM stock opened at $185.44 on Tuesday. Axsome Therapeutics, Inc. has a 52-week low of $86.99 and a 52-week high of $191.50. The stock’s fifty day simple moving average is $160.17 and its 200-day simple moving average is $133.94. The company has a quick ratio of 1.50, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $9.35 billion, a price-to-earnings ratio of -39.71, a price-to-earnings-growth ratio of 9.80 and a beta of 0.44.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The company had revenue of $170.99 million for the quarter, compared to analysts’ expectations of $162.96 million. Axsome Therapeutics’s revenue was up 63.2% on a year-over-year basis. Equities research analysts expect that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.